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ABSTRACT 
 
The human genome has millions of genetics variants that can affect gene expression. 
These variants are known as cis-regulatory variants and are responsible for intra-species 
phenotypic differences and individual susceptibility to disease. One of the diseases affected 
by cis-regulatory variants is breast cancer. Breast cancer is one of the most common cancers, 
with approximately 4500 new cases each year in Portugal. Breast cancer has many genes 
mutated and TP53 has been shown to be relevant for this disease. TP53 is one of the most 
commonly mutated genes in human cancer and it is involved in cell cycle regulation and 
apoptosis. Previous work by Maia et al has shown that TP53 has differential allelic 
expression (DAE), which suggests that this gene may be under the influence of cis-regulatory 
variants. Also, its DAE pattern is totally altered in breast tumours with normal copy number. 
We hypothesized that cis-regulatory variants affecting TP53 may have a role in breast cancer 
development and treatment. 
The present work aims to identify the cis-regulatory variants playing a role in TP53 
expression, using in silico, in vitro and in vivo approaches. By bioinformatic tools we have 
identified candidate cis-regulatory variants and predicted the possible transcription factor 
binding sites that they affect. By EMSA we studied DNA-protein interactions in this region of 
TP53. 
The in silico analysis allowed us to identified three candidate cis-regulatory SNPs which 
may affect the binding of seven transcription factors. However, the EMSA experiments have 
not been conclusive and we have not yet confirmed whether any of the identified SNPs are 
associated with gene expression control of TP53. We will carry out further experiments to 
validate our findings. 
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RESUMO 
 
As células normalmente crescem, dividem-se e morrem de uma forma controlada mas 
ao longo da vida surgem alguns danos no ADN. De forma a manter a função normal do 
organismo estes danos são reparados ou a célula entra em apoptose. Quando estes 
mecanismos falham pode ocorrer acumulação de mutações, o que leva à formação do 
cancro.  
O cancro não é uma doença única e homogénea, há sim uma grande variedade de 
cancros. O cancro da mama é um dos cancros mais comuns e em 2012, foi o quarto cancro 
com maior incidência em Portugal. Em cada ano existem 4500 novos casos e 1500 mulheres 
morrem com esta doença. No mundo, o cancro da mama representa cerca de 16% de todos 
os cancros femininos e 22.9% dos cancros invasivos na mulher. Esta doença é caraterizada 
por alterações nas células da mama que se tornam anormais e multiplicam-se 
descontroladamente levando à formação de um tumor. Estas alterações podem ser devido a 
fatores de risco, embora estes não sejam ainda bem compreendidos. Estes fatores incluem: 
idade, sexo, genética, história familiar, hormonas, contraceptivos, tumores benignos, entre 
outros.  
Existem muitos genes cujas mutações contribuem para a susceptibilidade do cancro da 
mama. Os genes frequentemente mutados são: BRCA1, BRCA2, ATM, TP53, CHECK2, PTEN, 
CDH1, STK11, entre outros. Mutações da linha germinal raras nos genes BRCA1 e BRCA2 
estão associadas a um alto risco e são responsáveis por aproximadamente 20% dos casos 
familiares. Mutações da linha germinal no gene TP53 são mais raras mas têm um risco muito 
elevado. Mutações somáticas no gene TP53 são encontradas também no cancro da mama 
em cerca de 15-20% dos tumores.  
O TP53 é um gene supressor de tumores que codifica uma proteína designada p53. A 
proteína p53 é um fator de transcrição e responde a vários stresses celulares através da 
regulação da expressão dos seus genes alvo. Esta proteína pode induzir paragem do ciclo 
celular, apoptose, senescência, reparação do DNA, ou alterações no metabolismo. O gene 
TP53 é um dos genes mais frequentemente mutado nos cancros. É um importante regulador 
homeostático, atuando na reparação do DNA, no controlo negativo do crescimento, em 
diversas vias de regulação do ciclo celular e apoptose. O TP53 tem muitos transcritos e 
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isoformas que resultam do splicing alternativo e da utilização de promotores e/ou codões de 
iniciação da tradução alternados. Este gene localiza-se no braço pequeno do cromossoma 17 
na posição 13.1 e é constituído por 11 exões. Frequentemente as mutações somáticas no 
TP53 são acompanhadas por perda de heterozigotia, indicando que o alelo normal residual é 
perdido em tumores.  
Milhões de variantes genéticas ocorrem no genoma humano e são designadas por 
polimorfismos. Estas variantes genéticas representam aproximadamente 1% do genoma. 
Existem algumas variantes que levam a numerosas diferenças fenotípicas e são responsáveis 
pela variabilidade intra-espécies. Os polimorfismos mais frequentes são os polimorfismos de 
um nucleótido (SNP) e constituem cerca de 90% de todas as variações conhecidas. Os SNPs 
localizados na região codificante de um gene podem levar a alterações de aminoácidos. Isto 
pode induzir a mudança de polaridade da proteína, alteração da configuração secundária e 
terciária da proteína, fosforilação inadequada, entre outras consequências funcionais. Os 
SNPs localizados na região não codificante são na maior parte considerados não funcionais. 
Todavia, este tipo de alterações pode afetar os elementos reguladores dos genes tais como 
promotores, amplificadores ou silenciadores, que podem estar próximo do gene, mas 
podem também estar à distância de centenas de kilobases do gene que regulam. Estes 
elementos reguladores podem coletivamente modular o tempo, magnitude e especificidade 
celular da expressão de um gene. 
SNPs cis-regulatórios são as variantes genéticas que afectam a expressão de um gene. 
Podem atuar através de diferentes mecanismos afetando por exemplo os sítios de ligação 
dos factores de transcrição (TFBS), modicações de histonas e metilação do DNA. O 
mecanismo mais comum é a modificação dos TFBSs.  
Uma área importante da pesquisa médica é a compreensão do papel dos SNPs cis-
regulatórios na doença. Como os SNPs cis-regulatórios originam um desiquilíbrio na 
expressão dos alelos de um gene, a análise da expressão alélica diferencial (DAE) é o método 
de excelência para estudá-los. Para estudar DAE compara-se a expressão relativa de dois 
alelos num indivíduo heterozigótico. A DAE é responsável pela variabilidade intra-espécie e 
pode levar ao aparecimento da susceptibilidade para doenças complexas. A variação nos 
elementos cis-regulatórios é comum no genoma humano e a DAE foi estimado a afetar 20-
50% dos genes, dependendo do método usado. Para identificar DAE, recentes estudos de 
genómicos de associação (GWAS) têm se focado na interpretação de SNPs codificantes ou 
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outros SNPs em regiões transcritas. O nosso grupo está principalmente interessado em 
estudar DAE na susceptibilidade do cancro da mama. Anteriormente, foi observado que o 
TP53 apresenta DAE e todos os indivíduos heterozigóticos expressam mais do mesmo alelo, 
no sangue e no tecido de mama. Isto indica que o SNP utilizado neste estudo está em 
completo linkage disequilibrium (LD) com a(s) variante(s) cis-regulatória(s). Como o sangue e 
o tecido de mama normais expressam o mesmo alelo, nós podemos concluir que o TP53 tem 
variantes cis-regulatórias.  
O objetivo deste estudo foi o de investigar se SNPs cis-regulatórios do TP53 têm algum 
efeito no cancro da mama. Para isso, nós propusemos mapear os SNPs cis-regulatórios que 
afetam a expressão do gene TP53 e prever TFBSs nesta região. 
Inicialmente, selecionámos o SNP (rs1042522) que previamente demonstrou expressão 
alélica diferencial no sangue e tecido de mama normais. As nossas análises in silico 
mostraram que rs1042522 está em completo LD com outro SNP (rs1642785). Isto levou-nos 
a investigar a região entre estes dois SNPs para modificações de histonas, zonas de 
hipersensibilidade à DNaseI e sítios de ligação de factores de transcrição. Descobrimos que 
neste intervalo há uma região muito ativa, com a possibilidade de existência de elementos 
reguladores. Outros quatro SNPs sobrepõem-se a este elementos e são candidatos para ser 
SNPs cis-regulatórios. Então analisámos os TFBSs para seis SNPs cis-regulatórios. Cada um 
destes SNPs tem dois alelos diferentes que são analisados individualmente para diferentes 
ligações de factores de transcrição (TF). Desses, três foram identificados como possíveis 
TFBSs que são expressos em tecido de mama, com diferenças para os dois alelos 
correspondentes.  
Para estudar se na sequência à volta destes SNPs cis-regulatórios candidatos pode 
realmente ligar-se algum TF, analisámos interações proteína-DNA através da técnica EMSA, 
usando oligonucleótidos contendo os SNPs de interesse. Realizámos várias experiências mas 
não detetámos nenhuma alteração, correspondendo a uma interação proteína-DNA positiva. 
No entanto, admitimos que o nosso extrato nuclear possa não estar funcional, dado que 
controlo positivo (FGFR2-13) usado para avaliar a qualidade dos extratos não mostrou uma 
alteração como era esperado. Existem duas possíveis explicações: (1) não existir realmente 
interação entre os TFs e os nossos oligonucleótidos, assim sendo estes SNPs não são cis-
regulatórios, e (2) o TF pode ligar aos nossos oligonucleótidos mas os extratos estão em boas 
condições. Iremos realizar mais experiências para resolver esta questão. Se a segunda 
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hipótese for confirmada, vamos confirmar se estes SNPs são ocupados in vivo pelos TFs 
respectivos através da técnica de imunoprecipitação da cromatina (ChIP). 
O objectivo central deste trabalho era estudar as variações cis-regulatórias do gene 
TP53 em cancro da mama. Não nos foi possível ainda confirmar se os SNPs existentes na 
região candidata são realmente cis-regulatórios e regulam a expressão do TP53 originando 
DAE. Como tal prosseguiremos os nossos estudos para clarificar a sua existência e função. 
Para confirmar o sue envolvimento em cancro da mama iremos também comparar os 
resultados finais entre tecido da mama normal e tumoral. 
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1. INTRODUCTION 
 
 
1.1 Cancer and Breast cancer 
Normal cells grow, divide and die controllably. During a person’s lifetime some damage 
occurs in the cell. In order to keep the normal function of the organism this damage can 
either be repaired or the cell can enter apoptosis. When these mechanisms fail, there can be 
an abnormal growth and/or division of the cells with further accumulation of mutations that 
can lead to cancer formation (Weinberg, 2007; Hanahan et al., 2011). 
Cancer is not a single disease, there are in fact many different kinds of cancers. Most 
cancers are designated according to the organ in which they start, such as lung, breast, 
colon, skin, among others, and/or type of cells in which they start; for example epithelial 
cells originate carcinomas, tumours of the connective tissues are called sarcomas and 
hematopoietic cells generate lymphomas or leukaemias. All cancers can be classified as in 
situ/non-invasive or invasive. In situ/non-invasive means that cancer has not yet invaded 
other tissues of the affected organ. Invasive means it has spread to other tissues of the 
affected organ (Strachan et al., 2010). Cancer cells can also spread to others parts of the 
body through the blood or lymph systems and settle in one or several organs. Over time, the 
cancer cells take the place of normal cells and give rise to metastases (Levin, 1913; 
Weinberg, 2007; Scully et al., 2012). 
Breast cancer is one of the most common cancers. In 2012, breast cancer was the fourth 
cancer with the highest incidence in Portugal (Figure 1.1). Each year there are 4500 new 
cases and 1500 women die of this disease. In the world, breast cancer accounts for 16% of all 
female cancers and 22.9% of invasive cancers in women (Jemal et al., 2010; http://www.eu-
cancer.iarc.fr/EUCAN/). 
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Figure 1.1 - Incidence of cancers in Portugal in 2012 (http://www.eu-cancer.iarc.fr/EUCAN/). 
 
This disease is characterized by alterations in breast cells, which become abnormal and 
multiply uncontrollably to form a tumour. These alterations can be due to risk factors, 
although not all are yet well understood. These factors include: age, sex, genetics, familial 
history, hormones, contraceptive pill, age of motherhood or childless, age of menarche and 
menopause, ethnic group, benign tumour, dense breast tissue, among others (Kelsey et al., 
1988). 
Breast cancer can begin in different areas of the breast, originating two mains types of 
breast cancer: ductal carcinoma and lobular carcinoma. Ductal carcinoma is the most 
common type of breast cancer and originates in the milk ducts. Lobular carcinoma is the 
second most common type of breast cancer and initiates in the lobules that produce milk 
and empty out into the ducts (Russnes et al., 2011). Breast cancer can also metastasize to 
many tissues throughout the body, but metastases often occur in bones, brain, liver and 
lungs. 
Most breast cancers can be sensitive to oestrogen because they express the oestrogen 
receptor on the surface of their cells, these are called oestrogen receptor-positive (ER+) 
cancers. This indicates that oestrogen lead to growth of breast tumour (Yerushalmi et al., 
2009). 
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Germline mutations may occur de novo or be inherited from parent’s germ cells – eggs 
or sperm – and can be transmitted to the next generation. Somatic mutations can occur in 
any cells in the body and the genes involved are usually located in autosomal chromosomes. 
These mutations are not passed along to the next generation. There are many genes whose 
germline mutations can contribute to breast cancer susceptibility (Weinberg, 2007). These 
include: BRCA1, BRCA2, ATM, TP53, CHECK2, PTEN, CDH1, STK11, among others. Rare 
germline mutations in BRCA1 and BRCA2 are associated with very high risk and are 
responsible for approximately 20% of familial cases. Germline mutations in TP53 are even 
more rare but have the highest risk (approximately 20-fold). Somatic mutations in TP53 are 
also found in breast cancer in about 15-20% of tumours (Hindorff et al., 2011). 
 
 
1.2 TP53 gene 
TP53 is a tumour suppressor gene that encodes a protein called p53. The p53 protein 
responds to diverse cellular stresses to regulate the expression of target genes. This protein 
induces cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. The 
activity of p53 is regulated by post-transcriptional, multiple transcriptional and translational 
mechanisms in response to a broad range of biological and physical stresses. This protein has 
consequently an important role in preventing DNA replication and cell division in conditions 
that damage genetic integrity (Liang et al., 2013). 
The TP53 gene is one of the most common mutated genes in human cancers. This gene 
is an important homeostatic regulator, acting over the DNA repair, negative growth control, 
multiple pathways of cell cycle regulation and apoptosis. TP53 has multiple transcript 
variants and isoforms that result from alternative splicing and the use of alternate 
translation initiation codon and/or promoters. This gene is located on the short (p) arm of 
chromosome 17 at position 13.1 and consist of 11 exons (Smith et al., 2011) (Figure 1.2). 
Germline mutations in TP53 occur in familial cases with Li-Fraumeni syndrome (LFS), 
which confer an increased risk of developing various cancers comprising mostly breast 
cancer, sarcoma, leukaemia and brain tumours. Breast cancer accounts for about 25% of all 
tumours in LFS patients and this syndrome can occur at any point in an individual’s lifetime, 
including childhood (Costa et al., 2008; Walerych et al., 2012). 
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TP53 somatic mutations are present in approximately 23% of breast cancers and this is 
second most mutated gene, where the PI3KCA proto-oncogene is the first most mutated 
gene. Usually somatic mutations in TP53 are accompanied by Loss of Heterozygosity (LOH) 
indicating that the remaining wild-type allele is also lost in the tumours (Strachan et al, 
2010). 
In breast cancer, the most investigated polymorphisms in TP53 are the Arg72Pro (a G to 
C transversion in codon 72 of exon 4), and the PIN3 Ins16bp (a 16 base pair duplication in 
intron 3). The TP53 Arg72Pro (rs1042522) results in an amino acid change from arginine to 
proline and is located in a proline-rich region of the protein, which has been known to be 
important for growth suppression and apoptotic functions. This polymorphism results in a 
structural change in the protein, giving rise to two isoforms of p53 that differ in biochemical 
and biological properties. However, several studies have indicated different functions for the 
two isoforms and these contradictory results have demonstrated that both TP53 Arg72Pro 
variants can differently regulate specific cellular functions (Dumont et al., 2003; Pim et al., 
2004; Ohayon et al., 2005). The PIN3 Ins16bp (rs17878362) has been reported to affect 
mRNA splicing, altering the coding regions and is implicated in the regulation of gene 
expression and DNA-protein interactions, which can result in a defective protein. 
Nevertheless, the biological effects of this polymorphism are not yet well understood. The 
TP53 Arg72Pro and PIN3 Ins16bp polymorphisms increase breast cancer in familial and 
sporadic cases (Costa et al., 2008; Guleria et al., 2012). 
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Figure 1.2 - TP53 gene structure and the different transcript variants. RefSeq genes mapped 
to the area of interest around the gene TP53 and Transcription Factor ChIP-seq according to 
the Genome Browser. In Transcription Factor ChIP-seq data, the black band means that the 
binding is stronger and more occupancy by transcription factors and the grey band indicate 
that binding is weaker and less occupancy by transcription factor. 
 
1.3 Cis-regulatory SNPs 
Millions of genetic variants occur in the human genome and are designated as 
polymorphisms. These genetic variants represent approximately 1% of the genome. There 
are some variants that cause numerous phenotypic differences and are responsible for intra-
species variability. Some genetic variants have little impact on human health but the 
majority of these variants can have a  strongly impact on disease susceptibility (Wilkins et al., 
2007; Vernot et al., 2012). Common polymorphisms include deletions, insertions and/or 
duplications of segments (copy number variations), sets of repeated segments (mini and/or 
microsatellites) and single nucleotide polymorphisms (SNPs). SNPs are very frequent 
polymorphisms and constitute about 90% of all known sequence variations. 
SNPs located within the coding region of a gene may cause amino acid alterations (non-
synonymous variants). These can induce protein polarity shift, misfolding, unsuitable 
phosphorylation and other functional consequences. SNPs located in non-coding regions are 
mostly considered as non-functional, nevertheless, this type of alterations can affect 
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regulatory elements of genes like enhancers, promoters or silencers, which may lie close to 
the gene, but can also be found hundreds of kilobases away from the gene that they 
regulate. These regulatory elements can collectively modulate timing, magnitude and cell-
specificity of gene expression (Pastinen et al., 2006). 
Cis-regulatory SNPs are the genetic variants that affect the gene expression. Cis-
regulatory SNPs can act through different mechanisms by affecting transcription factor 
binding sites (TFBS), histone modification and DNA methylation, for example. Probably the 
most common mechanism is the modification of TFBS. A SNP in a TFBS can have three main 
consequences: (1) a SNP may decrease or increase binding of a transcription factor (TF) and 
cause allele-specific gene expression alteration; (2) a SNP may delete an existing binding site 
or create a novel one; and (3) a SNP may not have any effect in the binding of the TF and 
consequently not change the expression, since a TF can recognize numerous binding sites. 
Therefore, a SNP in a TFBS can affect disease susceptibility because it can lead to differences 
in gene expression and phenotypes (Rockman et al., 2002; Serre et al., 2008; Maia et al., 
2012). 
 
1.4 Differential Allelic Expression 
An important area of medical research is the understanding of the role of cis-regulatory 
SNPs on disease. Because cis-regulatory SNPs generate imbalances in the expression of the 
alleles of a gene, differential allelic expression (DAE) analysis is a powerful method for 
studying them. To study DAE is to compare the relative expression of the two alleles in one 
heterozygous individual (Figure 1.3). In other words, the effect of cis-regulatory SNPs in a 
target gene can be detected by measuring the relative expression of the two alleles of that 
gene, by using transcribed SNPs in heterozygous individuals as allelic markers (Wilkins et al., 
2007; Maia et al., 2009).  
DAE is largely responsible for intra-species variability and can lead to the appearance of 
susceptibility to complex disease (Cheung et al., 2010). Variation in cis-regulatory elements is 
common in the human genome and DAE has been estimated to affect 20-50% of genes, 
depending on the method used. Some studies have reported that genes demonstrating DAE 
are tissue specific, with differences in allelic expression referred to liver, brain, kidney and 
spleen. To identify DAE that is likely to play an important biological role, recent genome-
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wide association studies (GWAS) have been focused on the interpretation of coding or other 
SNPs in transcribed regions (Wilkins et al., 2007; Gagneur et al., 2009). 
 
 
Figure 1.3 - Differential allelic expression analysis. 
 
Our group is mainly interested in studying DAE in breast cancer susceptibility. 
Previously, it has been observed that TP53 displays DAE and all heterozygous individuals 
express more of the same allele, both in blood and breast tissue (Figure 1.4). Because the 
allelic expression ratio is in log scale in Figure 1.4, all of the individuals near 0 express the 
two alleles equally but the individuals that are distant from 0 express more of one allele, i.e. 
have DAE. In the case of TP53, all of the heterozygous individuals express more of the same 
allele, indicating that the marker SNP is in complete linkage disequilibrium (LD) with the cis-
regulatory variant (or variants). As normal blood and normal breast tissue express the same 
allele, we can conclude that TP53 have cis-regulatory variants. 
 
 
Figure 1.4 - Comparison of DAE in blood and breast tissue in different genes. Heterozygous 
individuals are represented as dots. The numbers in parentheses are the quantity of 
individuals studied for each sample (adapted from Maia et al., 2009). 
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Preliminary data from our group also indicates that tumours have a completely different 
DAE pattern from control blood and normal breast tissue (Figure 1.5). The control and 
normal breast samples exhibit a unilateral allelic expression. And the tumours samples show 
a wide bidirectional variation in the allelic expression, with the allelic expression in these 
samples showing a large discrepancy. Consequently, this can have consequences on the 
characteristics of tumours. 
Therefore, we are interested in studying whether cis-regulatory polymorphisms of TP53 
are involved in the susceptibility to breast cancer as well as in determining the clinical 
characteristics of tumours. 
 
 
Figure 1.5 - DAE analysis of TP53 in control, normal breast and tumours. “ControlS” 
corresponds to control blood, the “Tumours” correspond to breast tumours and the “Normal 
Breast” corresponds to normal breast tissue. Each circle represents a heterozygous 
individual and “n=” represent the number of samples. The p-value corresponds to an F test 
to compare the variance of the three groups. (Maia AT personal communication). 
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1.5 Aims 
The main goal of the present work was to map the cis-regulatory variants of TP53 in 
breast cancer. The specific aims of this work were:  
 
1. Identification of candidate cis-regulatory SNPs in the gene TP53; 
2. prediction of transcription factor binding sites in this locus through in silico 
analysis; 
3. study DNA-protein interactions through in vitro and in vivo analysis. 
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2 MATERIALS AND METHODS 
 
 
2.1 Cell lines and cell culture 
In this study, we used different cell lines: breast cancer (MCF-7, T47D, HCC1954 and 
MDA-MB-436) and lymphoblastoid (GM12878 and GM06991) for nucleic acid and nuclear 
protein extraction. 
Breast cancer cell lines MCF-7 and T47D are positive for oestrogen receptor and derived 
from invasive ductal carcinoma (Keydar et al., 1979; Soule et al., 1990), HCC1954 is negative 
for oestrogen receptor and derived from a ductal carcinoma (Gazdar et al., 1998) and MDA-
MB-436 (Cailleau et al., 1978) is negative for oestrogen receptor and derived from an 
invasive ductal carcinoma (Di Leva et al., 2013). These cell lines were kindly provided by Dr. 
Suet-Feung Chin of the University from Cambridge. 
Lymphoblastoid cell lines GM12878 and GM06991 were obtained from the Centre 
d’Étude du Polymorphisme Humain (CEPH) collection, which is an international resource of 
cultured lymphoblastoid cell lines (LCL) from 1050 individuals in 52 world populations. 
MCF-7 and T47D cell lines were cultured in DMEM medium (Dulbecco’s Modified Eagle 
Medium), HCC1954, GM12878 and GM06991 cell lines were cultured in RPMI1640 medium 
(Roswell Park Memorial Institute) and MDA-MB-436 cell line was cultured in Leibovitz’s L-15 
medium. All culture media were supplemented with 10% foetal bovine serum (FBS) and 1% 
penicillin/streptomycin. All media and supplements were obtained from Invitrogen. These 
cell lines were incubated at 37oC with 5% CO2.  
For sub-culturing cells, the culture medium was removed from the T-flask and the cells 
were washed with PBS 1x (Sigma), to withdraw all residues and dead cells. Then, Tripsin-
EDTA solution was added and the cells were incubated at 37oC for 2 minutes to facilitate the 
dispersion of the cell layer. The cells were observed under an inverted microscope to ensure 
that the cell layer was dispersed throughout. Complete growth medium was then added and 
the cells were resuspended and transferred to a centrifuge tube. The cell suspension was 
centrifuged at approximately 300rpm for 5 minutes, and the supernatant was discarded. The 
cell pellet was resuspended in fresh growth medium and divided into new T-flasks.  
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For freezing cells, the procedure described above was performed with the exception 
that complete growth medium was supplemented with 5% DMSO (Sigma). The cell 
suspension was aliquoted in vials and these were placed in a freezing container (Nalgene) at 
-80oC. The freezing container has isopropyl alcohol that allows a rate of cooling 
approximately of 1oC/minute, which does not compromise cell viability. 
For thawing cells, the cell vial was placed in a 37oC water bath with gentle agitation. The 
vial was removed from the water bath as soon as the contents were thawed. The cell 
suspension was removed immediately to a centrifuge tube that was prepared previously 
with 10ml of culture medium. This was centrifuged at approximately 300rpm during 5 
minutes. The supernatant was discarded and the cell pellet was resuspended in 5ml of fresh 
growth medium. The cells were transferred to a 25cm2 T-flask and were observed under an 
inverted microscope and incubated as described above. 
 
 
2.2 Nucleic acid extraction and processing 
Genomic DNA was extracted from the cell lines with the QIAamp DNA Mini kit (QIAGEN) 
following the manufacturer’s instructions. Initially, 5 x 106 cells were centrifuged at 300xg for 
5 minutes. The pellet was resuspended in 200µl PBS and 20µl of proteinase K were added. 
200µl Buffer AL were then added and mixed thoroughly, followed by an incubation at 56oC 
for 10 min. 200µl ethanol (100%) were added to the sample and mixed by vortexing. The 
mixture was pipetted into the DNeasy Mini spin column and centrifuged at 6000xg for 1 
minute. Next, 500µl Buffer AW1 were added, followed by a centrifugation at 6000xg for 1 
minute. 500µl Buffer AW2 was added in column and centrifuged at 20,000xg for 3 minutes 
to dry the DNeasy membrane. The column was placed in a clean tube and 200µl Buffer AE 
were pipetted directly onto the DNeasy membrane. This column was incubated at room 
temperature for 1 minute and then was centrifuged at 6000xg for 1 minute to elute. 
Total RNA was extracted from the cell lines using TRI Reagent (Sigma-Aldrich). The TRI 
Reagent is a monophasic solution of phenol and guanidine thiocyanate that at the same time 
dissolves DNA, RNA, and protein on homogenization or lysis of tissue sample. For monolayer 
cells (MCF-7, T47D, HCC1954 and MDA-MB-436 cell lines), 1ml of the TRI Reagent was added 
per flask. Then, the cell lysate was passed several times through a pipette to form a 
homogenous lysate. For suspension cells (GM12878 and GM06991 cell lines) 5-10x106 cells 
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were centrifuged and then lysed in 1ml of TRI Reagent, with repeated pipetting. To ensure 
complete dissociation of nucleoprotein complexes, the samples were left for 5 minutes at 
room temperature and then 0.2ml of chloroform (Merck) per ml of TRI Reagent were added. 
The chloroform is used to separate DNA, RNA and proteins in different phases. The samples 
were mixed vigorously for 15 seconds and incubated at room temperature, during 15 
minutes. The mixture was centrifuged at 12,000g for 15 minutes, at 4oC. Centrifugation 
separated the mixture into 3 phases: a red organic phase (containing protein), an interphase 
(containing DNA) and a colourless upper aqueous phase (containing RNA). The aqueous 
phase was transferred to a fresh tube and added 0.5ml of isopropanol (Sigma) per ml of TRI 
Reagent. The isopropanol serves to precipitate the RNA, originating a pellet after 
centrifugation. The sample stood 5-10 minutes at room temperature and then was 
centrifuged at 12,000g for 10 minutes at 4oC. The supernatant was removed and the RNA 
pellet was washed by adding 1ml of 75% ethanol per ml of TRI Reagent. 75% ethanol is used 
as a wash solution because RNA is a precipitate in this percentage of ethanol, while most 
proteins and salts remain in solution. The sample was vortexed and then centrifuged at 
7,500g for 5 minutes, at 4oC. The RNA pellet was air-dried for 5-10 minutes and then an 
appropriated volume of water was added and mixed by repeated pipetting. The RNA was 
subsequently treated with DNase. For DNase treatment, the reactions were performed 
using: 2U of RNase-Free DNase, 1µl of RNase-Free DNase 10x Reaction Buffer, 1µg of RNA 
and Nuclease-free water to a final volume of 10µl. The samples were incubated at 37oC for 
30 minutes. Then, the reaction was terminated with the addition of 1µl of DNase Stop 
Solution and incubated at 65oC, for 10 minutes. All the reagents used for DNase treatment 
were purchased from Invitrogen. 
cDNA was prepared from total RNA with Super-Script III First Strand SuperMix 
(Invitrogen) using oligo-dT primer according to manufacturer’s instructions. For First Strand 
cDNA Synthesis, the reactions were performed using: 5µg of total RNA, 50µM oligo(dT), 1µl 
of annealing buffer and RNase/DNase-free water in a final volume of 10µl. The PCR tubes 
were incubated at 65oC for 5 minutes, immediately put on ice for at least 1 minute and then 
10µl of First-Strand Reaction Mix and 2µl of SuperScript III/RNaseOUT Enzyme Mix were 
added. The samples were briefly vortexed and collected by centrifugation, and then 
incubated at 50oC, for 5 minutes. To terminate the reaction, the samples were incubated at 
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85oC, for 5 minutes and then placed on ice. The cDNA synthesis reactions were stored at -
20oC. 
 
 
2.3 Quantification of DNA and RNA 
DNA and RNA concentrations were assessed with the Thermo Scientific NanoDrop 2000c 
Spectrophotometer. Spectrophotometric analysis is one of the more commonly used as a 
measure of quantity and purity of nucleic acid, as this absorbs ultraviolet light in a specific 
pattern. DNA and RNA samples are exposed to ultraviolet light at 260 nanometres (nm) and 
a photodetector measures the ultraviolet light which passes through the samples. The ratio 
of the absorbance at 260 and 280nm is used to measure the purity of nucleic acid. For DNA, 
a pure sample will yield a ratio of approximately 1.8. A pure RNA sample will yield a ratio of 
approximately 2.0. The ratio is frequently used to assess the contamination; it may indicate 
the presence of protein, phenol or other contamination that absorb light at 280nm. 
 
 
2.4 SNPs and haplotype analyses 
HapMap is a catalogue of common human genetic variants, resulting from an 
international effort. It contains information on location and population distribution of these 
genetic variants. HapMap release #27 (http://www.hapmap.ncbi.nlm.nih.gov/) was accessed 
to download the genotyping data of the area of interest around the gene TP53. Haploview 
software (http://www.broadinstitute.org/haploview) was used for the analysis of haplotype 
and linkage disequilibrium. Genome Browser (http://genome.ucsc.edu/) was accessed to 
analyse the region selected. This site contains the reference sequence of the human 
genome, amongst others, and data from the ENCODE project, on regulatory elements of our 
genome. 
 
 
2.5 in silico prediction of transcription factor binding sites 
The prediction of transcription factor binding sites (TFBS) started with the analysis of our 
region of interest with different TF search engines such as the Jaspar database, the 
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Genomatix software and the ALGGEN website. Jaspar database, version 6.0_ALPHA 
(http://jaspar.binf.ku.dk/) is a collection of smaller databases (TRANSFAC, etc). Genomatix 
software suite (http://www.genomatix.de, Genomatix Software GmbH, Munich, 
Germany)(Quandtl et al., 1995) uses the MatInspector release 8.0.6 (Cartharius et al., 2005). 
ALGGEN website (http://alggen.lsi.upc.es/) uses PROMO with version 8.3 of TRANSFAC. We 
analysed the region surrounding all the SNPs, as well as used the sequences with the 
different alleles for each SNP. We used a cut-off of 0.9 for the matrix and the core similarity 
score that correspond to the quality of a match between DNA sequence and TF binding 
matrix. 
 
 
2.6 Mobility shift DNA – binding assay 
 
2.6.1 General description of the assay 
Electrophoretic Mobility Shift Assay (EMSA) is a powerful technique that allows in vitro 
detection of the interaction between a protein and a labelled DNA probe. In the assay a 
labelled double-stranded oligonucleotide containing a known sequence with a putative TFBS 
is added to the nuclear extract, thereby allowing DNA-protein complexes to form. The DNA-
protein probe mixture is loaded on a polyacrylamide gel and electrophoresed. If proteins are 
bound to the labelled DNA, the protein-DNA complex will migrate more slowly through the 
gel, creating a shift relative to the unbound oligonucleotide. 
Binding affinity of a particular protein for a target binding sequence is distinguished with 
competitive EMSA by the use of competing non-labelled sequences in the binding reaction. 
Additionally, antibodies that recognize epitopes of a bound protein generate a decrease 
mobile protein-DNA complex, resulting in a supershift on the gel which indicates specificity 
of DNA-protein binding (Jiang et al., 2010; Pagano et al., 2011). 
 
2.6.2 Preparation of Nuclear Extracts 
2-6x107 cells were harvested with the addition of Tripsin-EDTA solution to facilitate the 
dispersion of the cell layer, and centrifuged at 1500rpm for 5 minutes to pellet; subsequent 
steps were performed at 4oC. Pelleted cells were re-suspended in 1ml of PBS 1x to withdraw 
all residues and dead cells and then collected by centrifugation at full speed for 25 seconds. 
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The cells were resuspended in 250µl of HB buffer (10mM Tris pH 7.4, 10mM KCl (Sigma), 
1.5mM MgCl (USB), 1mM DTT and 1x Protease Inhibitor (PI) (Roche)) and centrifuged at full 
speed for 25 seconds. The cells were resuspended in 300µl of HB buffer with 0.4% of NP40 
(Fluka) and left on ice for 5 minutes. Then, the cells were centrifuged at full speed for 5 
minutes, frozen in liquid N2 and storage at -80
oC. The pellet was resuspended in 100µl of 
buffer C (20Mm Hepes (Sigma) pH 7.9, 0.4M NaCl (Merck), 1mM EDTA, 20% Glycerol (VWR), 
1mM DTT and 1x PI)/ 2x107 cells. The tubes were vigorously rocked at max speed for 30 
minutes and then centrifuged at full speed for 5 minutes. The supernatant, designated as the 
nuclear extract, was used immediately. 
 
2.6.3 Determination of total protein concentration 
Nuclear extract concentration was assessed with the Qubit 2.0 Fluorometer (Life 
Technologies) according to the manufacturer’s instructions. A working solution was made by 
diluting the Qubit Reagent in Qubit Buffer (1:200) in appropriate PCR tubes. This assay 
requires three standards tubes with 190µl of working solution and 10µl of Qubit standards. 
The same process was made for the nuclear extract samples. PCR tubes were mixed by 
vortexing and incubated at room temperature for 15 minutes. Then, the standards were 
measured first to calibrate the Qubit 2.0 Fluorometer followed by the samples. 
This method uses a fluorescent dye (Qubit dye) that intercalates nucleic acid or protein 
to determine its concentration. The amount of fluorescence signal from the mixture is 
directly proportional to the concentration of nucleic acid or protein in the sample solution. 
The Qubit fluorometer reads this fluorescence signal and extrapolates the sample 
concentration by using the Qubit standards of known concentration.  
 
2.6.4 Preparation of DNA probes 
Primers were designed in the regions that contain the selected SNPs and are 
summarized in Table 2.2. Single-stranded DNA probes (Invitrogen) and unlabelled control 
were labelled with Biotin 3’ End DNA Labelling Kit (Thermo Scientific). For the labelling 
reaction, in a total volume of 50µl, 25µl of ultrapure water were mixed with 1x TdT Reaction 
Buffer, 100nM Unlabeled Oligos, 0.5µM Biotin-11-UTP and 10U Diluted TdT. The reaction 
mixture was incubated at 37oC for 30 minutes, and then 2.5µl of 0.2 M EDTA were added to 
stop the reaction. 50µl of chloroform:isoamyl alcohol (24:1) (Sigma) were added to the 
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mixture to extract the TdT, and the phases were separated through centrifugation at high 
speed for 2 minutes. The complementary oligos that were end-labelled separately were then 
annealed by mixing together equal amounts of labelled complementary oligos and incubated 
at 80oC for 10 minutes and then at room temperature for at least 3 hours. 
 
Table 2.1 – Primers designed for EMSA. 
*The underlined nucleotides indicate the SNPs; - : indicates the deletions 
 
The labelling efficiency was determined by dot blot using hand spotting following the 
manufacturer’s instructions. The samples and standards were put onto the nylon membrane 
(Thermo Scientific) that was previously hydrated in TE buffer (10mM Tris pH 8.0 and 1mM 
EDTA) and the crosslink of the membrane was performed in a transilluminator with the 
membrane face down, for 15 minutes.  
For the detection of the spotted standards and samples, the Streptavidin-Horseradish 
Peroxidase Conjugate was used together with the Chemiluminescent Substrate from the 
Chemiluminescent Nucleic Acid Detection Module (Thermo Scientific). To determine the 
labelling efficiency the spot intensities of the samples were compared to those of the Biotin-
EBNA Control DNA. 
SNPs Alleles Strand Sequence* Primer
Forward GCAGGGGCCACGGGGGGAGCAGCCT ATM1
Reverse AGGCTGCTCCCCCCGTGGCCCCTGC ATM2
Forward GCAGGGGCCACGCGGGGAGCAGCCT ATM3
Reverse AGGCTGCTCCCCGCGTGGCCCCTGC ATM4
Forward
TCAGCCCCCCAGCCCCCCAGCCCTCCAGGTCCCCAGCCC
TCCAGGTCCCCAGCCCAACCC
ATM13
Reverse
GGGTTGGGCTGGGGACCTGGAGGGCTGGGGACCTGGA
GGGCTGGGGGGCTGGGGGGCTGA
ATM14
Forward
CCAGGTCCTCAGCCCCCCAGCC-
CCCCAGCCCTCCAGGTCCCCAGCCCAACCCTTGTCCTT
ATM15
Reverse
AAGGACAAGGGTTGGGCTGGGGACCTGGAGGGCTGGG
G-GGCTGGGGGGCTGAGGACCTGG
ATM16
Forward GTCAGTCCCATGGAATTTTCGCTTC ATM17
Reverse GAAGCGAAAATTCCATGGGACTGAC ATM18
Forward GTCAGTCCCATG-AATTTTCGCTTTC ATM19
Reverse GAAAGCGAAAATT-CATGGGACTGAC ATM20
Forward CTCTATGCAAATATGCGGTTTGGAGCAGGG FGFR2-13
Reverse CCCTGCTCCAAACCGCATATTTGCATAGAG FGFR2-13
G
rs2307496
rs17878362
rs1042522
rs2981578
G
C
CCCCAGCCCTCCAGG
T
-
G
-
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2.6.5 Identification of DNA-protein binding reaction 
EMSA were performed with LightShift Chemiluminescent EMSA Kit (Thermo Scientific) 
according to manufacturer’s instructions. A 6% polyacrylamide gel was prepared as follows: 
7333µl of H2O, 125µl of 5xTBE (450mM Tris, 450mM boric acid (Sigma), 10mM EDTA), 
1000µl of Glycerol, 1500µl of 30% acrylamide (Ambion), 30µl of 20% APS (Sigma) and 12µl of 
TEMED (Nzytech). The gel was pre-run for 30 minutes at 100V. A complete set of three 
reactions were performed for each SNP and for Biotin-EBNA control DNA (summarized in 
Table 2.4) and the binding reactions were incubated at room temperature, for 20 minutes. 
To each 20µl binding reaction, 5µl of 5X Loading Buffer was added and then 20µl of each 
sample was loaded onto the wells of the polyacrylamide gel. 
After the electrophoresis, the binding reactions on the polyacrylamide gel were 
transferred onto a nylon membrane and were sandwiched between three chromatography 
paper sheets on each side soaked in transfer buffer (0.5X TBE). The transfer was carried out 
by a Trans-Blot SD Smi-Dry Transfer Cell (Bio-Rad) at 20V, for 25 minutes. Crosslink and 
detection were performed as described in Section 2.7.4. 
 
Table 2.2- Binding reaction calculations used for each SNP 
Component Final Amount 
Reaction 
1 2 3 
Ultrapure water - 12µl µl µl 
10X Binding Buffer 1X 2µl 2µl 2µl 
1µg/µl Poly (dI·dC) 50ng/µl 1µl 1µl 1µl 
50% Glycerol 2.5% 1µl 1µl 1µl 
1% NP-40 0.05% 1µl 1µl 1µl 
100Mm MgCl2 5mM 1µl 1µl 1µl 
Unlabelled Target DNA 4pmol - -  
Protein Extract  -   
Biotin End-Labelled Target DNA 20fmol    
Total volume - 20µl 20µl 20µl 
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2.7 Genotyping 
Genomic DNA from cell lines, as described in Section 2.2, was amplified by the 
Polymerase Chain Reaction (PCR) in a total volume of 50µl. The reactions were performed 
with 50ng of genomic DNA, 1x PCR buffer, 2,5mM of MgCl2, 0.2mM of deoxynucleotidyl 
triphosphates (dNTPs), 0.125µM of each primer (Table 2.1) and 5U of Taq DNA Polymerase 
(all from Invitrogen). The reaction mixture was initially incubated for 2 minutes at 95ºC and 
then submitted to 35 cycles including in each one denaturing (30 seconds at 95ºC), annealing 
(30 seconds at 60ºC) and extension (45 seconds at 72ºC) steps, and a final extension step of 
7 minutes at 72ºC.  
cDNA samples obtained from cell lines was used in a PCR reaction with the same 
conditions. 
Specific forward and reverse primers for the region around the selected SNPs were 
designed with Primer3 program (available at http://frodo.wi.mit.edu/), and are summarized 
in Table 2.3.  
 
Table 2.3- Primers for the region around the selected SNPs. 
 Strand Oligonucleotides 
DNA 
Forward GCCAGGCATTGAAGTCTCAT 
Reverse TGGAAGTGTCTCATGCTGGA 
cDNA 
Forward CCCCTCTGAGTCAGGAAACA 
Reverse AGAATGCAAGAAGCCCAGAC 
 
 
The resulting PCR products were submitted to electrophoresis in 1.5% agarose gel 
(UltrapureTM Agarose, Invitrogen) prepared with 1x TAE buffer (40mM Tris (Sigma), 20mM 
acetic acid (Merck), 1mM EDTA (Sigma)) and 2.5µl/100 ml GreenSafe (Nzytech). A Gene 
Ruler 1kb (Thermo Scientific) was used as a DNA size marker. The gels were visualized using 
UV transilluminator (Gel Image Analyser, GelDoc 2000, BioRad). 
The DNA fragments of interest were excised from the agarose gel and extracted using 
QIAquick PCR Purification Kit (QIAGEN), according to the manufacturer’s instructions. The 
final product was diluted in 30 µl of ultrapure water (Sigma).  
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The DNA sequencing was performed in the Centre of Marine Sciences (CCMAR; Serviço 
de Biologia Molecular). CCMAR used Sanger sequencing with BigDye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems). 
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3 RESULTS 
 
 
3.1 in silico analysis 
The genotyping data of area of the interest around TP53 was collected from HapMap 
release #27. HapMap is a database with genotyping information of a large proportion of 
SNPs, obtained from normal controls. Then this genotyping data was inserted in the 
Haploview software. In this software the haplotype structure and linkage disequilibrium (LD) 
of this region were analysed. LD is the higher probability of two alleles of two SNPs being 
inherited together, than it would be expected by chance alone. In Haploview software, we 
identified two main haplotype blocks (Figure 3.1) corresponding in block 1 to two haplotypes 
and in block 2 to four haplotypes in the European population (CEU samples in HapMap) 
(Figure 3.2). SNP rs1042522 was used by Maia et al (2009) as a marker SNP in a breast tissue 
DAE study, and we searched for SNPs in complete LD with it, as all heterozygotes identified 
in that study had the same allele being preferentially expressed. rs1042522 is included in 
block 2, in which haplotype 1 is the most common in the European population, with an 
approximate frequency of 72%. Our results showed that the SNP rs1642785 is in complete 
LD with rs1042522 (Figure 3.2). Both allele C in rs1042522 and allele C in rs1642785 are the 
most frequent in the population. They are in complete LD so when one SNP has allele C the 
other SNP has allele C, as we can see in Figure 3.2. The allele C of rs1042522 has a frequency 
of 74% that corresponds to the haplotype 1 and haplotype 4. 
 Figure 3.1 - LD plot for the region around TP53. Two main haplotype blocks (black triangles) were identified. The red squares denote the pairs 
of SNPs with stronger LD and the light blue squares are those with weaker LD. The two SNPs that were selected for this study are shown in 
green (http://www.broadinstitute.org/haploview). 
 Figure 3.2 - Haplotype blocks and haplotype frequencies in TP53. In green rectangle are the 
two SNPs selected and each letter corresponds to one allele of each SNP. The SNPs 8 and 11 
are, respectively rs1042522 and rs1642785 (http://www.broadinstitute.org/haploview). 
 
In Haploview analysis we only obtained two SNPs, then we analysed the region between 
this two SNPs using the UCSC Genome Browser. This region has the possible existence of 
regulators elements where there can be cis-regulatory SNPs. The Genome Browser contains 
the reference sequence for a large collection of genomes, plus information on histone 
modifications and DNAse hypersensitivity regions. The histone modifications indicate the 
possibility of existence of enhancers, promoters and other regulatory elements. The DNAse 
hypersensitivity regions or clusters are areas of open chromatin that indicate the presence 
of active chromatin (see in Genome Browser according with The ENCODE Project 
Consortium, 2011). We used this information to investigate whether our region of interest 
had potential regulatory elements. In the Genome Browser there is the indication that this 
region may contain binding sites for several transcription factors. In the version Human Feb. 
2009 (GRCh/hg19) Assembly from Genome Browser, we observed the possible existence of 
SNPs in the region between two SNPs selected in Haploview. And here we found four SNPs 
that are in overlap with regions containing possible regulatory elements (Figure 3.3). Two of 
these SNPs (rs1042522 and rs1800370) are in the coding region (exon 4) and the other four 
(rs17883323, rs1787832, rs2307496 and rs1642785) are in non-coding regions (first two are 
found in intron 3 and the others in intron 2), as shown the Figure 3.3. 
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Figure 3.3 - Diagram of the TP53 gene. RefSeq genes mapped to the area of interest around 
the gene TP53, position of SNPs and regions where there are histone modifications, DNAse 
clusters and transcription factors according to the Genome Browser 
(http://genome.ucsc.edu/). 
 
 
3.2 Transcription factor binding sites results 
Initially, we analysed the putative transcription factor binding sites (TFBS) in three 
different websites that are: Jaspar database, Genomatix software and ALGGEN. In this 
analysis we included the sequence around all SNPs with the two different alleles, to search 
for allelic differences in TF binding. Different TFBS were observed for each allele but only to 
three SNPs the predicted TF is known to be expressed in breast tissue (Table 3.2). Although 
the two alleles of rs17878362 have the same TF predicted we selected them because this 
SNP has a large allele (sequence with 16 alleles) that can have consequences on the number 
of possible TFs binding. SNP rs2307496 in G allele has one possible transcription factor and 
in the allele with a deletion there are two possible transcription factors. In rs1042522 there 
are two possible TFs binding in the presence of allele G that are not in present for allele C.  
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Table 3.1 - SNPs selected for analysis of TFBS. 
SNPs Alleles Transcription Factor 
rs17878362 
CCCCAGCCCTCCAGGT 
SP1, CTCF 
- 
rs2307496 
G HMGY 
- HMGY, ETS1  
rs1642785 
G - 
C - 
rs1042522 
G NMYC, HIF 
C - 
 
 
 
3.3 in vitro analysis 
 
3.3.1 Identification of DNA-protein binding 
The EMSA is used for studying DNA-protein interactions. For EMSA, we prepared protein 
nuclear extract from MCF-7, T47D, HCC1954 and GM12878 cell lines. The primers containing 
the SNPs of interest (Table 2.1) and the EMSA control primer (FGFR2-13) were labelled with 
biotin. The FGFR2-13 has been reported to show binding in EMSAs using nuclear extracts 
from these cell lines (Meyer et al., 2008). The level of labelling of all primers was between 
75-100% of the Biotin-EBNA Control DNA, as shown in Figure 3.4.  
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Figure 3.4 - Level of labelling from all primers and Biotin-EBNA Control DNA. (A) Detection of 
labelling from FGFR2-13 and Biotin-EBNA Control DNA. (B) Detection of labelling from all 
SNPs. 
 
The Biotin-EBNA Control DNA was tested and EMSA was performed for nuclear extract 
of MCF-7, T47D, HCC1954 and GM12878 cell lines with primers detailed in Table 2.1. Initially, 
we tested the SNPs for all cell lines and saw that the shift did not occur (Figure3.5A). 
However, when we tested a control primer (FGFR2-13) for the nuclear extracts, this did not 
produce a shift as well (Figure 3.5B). This primer has previously been shown to bind to Oct1 
and Runx2 (Meyer et al. 2008). This result suggests that our nuclear extracts were not 
working. Amongst other possibilities, we believe that the temperature of the laboratories at 
the time of preparation of the nuclear extracts was too high and may have interfered with 
the efficiency of the preparation. Therefore, we propose to re-extract the nuclear proteins 
this time using a different protocol, the NE-PER Nuclear and Cytoplasmic Extraction Reagents 
(Thermo Scientific), and keeping strict temperature control of our experiments. 
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Figure 3.5 – in vitro DNA-protein binding studies. (A) Analysis of rs1042522, using MCF-7 cell 
extract. (B) Analysis of FGFR2-13 (control positive) and rs1042522, using T47D cell extract. In 
both analysis was tested Biotin-EBNA Control DNA. Arrows indicate specific bands for DNA-
protein interactions of Biotin-EBNA Control DNA. *: represent the primers labelled. 
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3.4 Genotyping analysis 
In HapMap there is genotyping information for SNPs rs1642785 and rs1042522. 
Therefore, all other SNPs were sequenced to determine the genotype in all cell lines. The 
aim of genotyping is to define which cell lines should be used for Chromatin 
Immunoprecipitation (ChIP). In Genome Browser there is no information from ENCODE on 
the breast cancer cell lines we are using but there is information on the lymphoblastoid cell 
lines (GM12878 and GM06991). Therefore, lymphoblastoid cell lines are the positive 
controls for the ChIP analysis. Genotyping of the breast cancer and lymphoblastoid cell lines 
was performed by PCR amplification of the region of interest followed by direct sequencing. 
The genotype is heterozygous only for three SNPs in GM12878 cell lines (Figure 3.6), all 
other SNPs are homozygous for all cell lines (Table 3.2).  
 
 
Table 3.2 - Analysis of genotype from different cell lines. 
SNPs MAF Region 
Cell lines 
MCF-7 T47D HCC1954 MDA-MB436 GM12878 GM06991 
rs1642785 36.4 Non-Coding CC CC ND ND CG ND 
rs2307496 NA Non-Coding +/+ +/+ ND ND +/+ ND 
rs17878362 NA Non-Coding -/- +/+ ND ND +/- ND 
rs17883323 7.3 Non-Coding AA CC ND ND CC ND 
rs1800370 1.2 Coding GG GG CC CC GG CC 
rs1042522 39.8 Coding CC CC GG CC CG CC 
MAF: Minor Allele Frequency; ND: Not Determined; NA: Not Available. 
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Figure 3.6 - Results of sequencing from heterozygous SNPs in GM12878 cell line. (A) 
rs1642785 is in negative strand and has the allele C and allele G. (B) rs17878362 is in 
negative strand, this SNP is a deletion of the sequence ACCTGGAGGGCTGGGG. (C) rs1042522 
is in positive strand and has the allele C and allele G. Black rectangles indicate the position of 
the SNPs. 
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DISCUSSION 
 
Our aim in this study was to investigate whether cis-regulatory SNPs of TP53 have any 
effect in breast cancer. For this, we proposed to map the cis-regulatory SNPs affecting the 
gene expression of TP53 and the predicted TFBSs in this region. 
Initially, we chose the SNP (rs1042522) that showed previously differential allelic 
expression in normal breast tissue and blood (Maia et al., 2009). Our in silico analysis 
showed that rs1042522 is in complete LD with another SNP (rs1642785). This led us to 
decide to investigate the region between these two SNPs for histone modifications, DNase 
clusters and transcription factors binding sites. We found that in this interval there is a very 
active region, with the possibility of existence of regulatory elements. Four other SNPs 
overlap these elements and are candidates to be cis-regulatory SNPs. So, we analysed the 
TFBSs for six cis-regulatory SNPs in total. Each of these SNPs has two different alleles, which 
were analysed individually for differential TF binding. Three were identified to have possible 
TFBSs that are expressed in breast tissue, with differences for the two corresponding alleles. 
SNP rs17878362 has the same TFBS predicted for both alleles (for SP1 and CTCF) and we 
selected it because we think that the large deletion allele can have consequences in terms of 
numbers of TFs binding (SP1 has different number of binding sites for each allele). The G 
allele of SNP rs2307496 has one possible TFBS (for HMGA2). The alternative allele, with a 
deletion in that position, hast two possible TFBS (for HMGA2 and ETS1). In rs1042622 there 
are two possible TFBS (for NMYC and HIF1) in presence of G allele that do not appear in the 
presence of the C allele. 
All of these transcription factors have been reported to be involved in cancer. Specific 
protein 1 (SP1) is a transcription factor that regulates the expression of many genes involved 
in processes like differentiation, cell growth, apoptosis, among others (Zhang et al., 2013). 
CCCT-binding Factor (CTCF) is a transcription factor and an epigenetic regulator that is 
associated with Wilms tumours, breast cancer and prostate cancer (Ross-Innes et al., 2011). 
High mobility group AT-HOOK 2 (HMGA2) participates in a wide variety of cellular processes 
like induction of neoplastic transformation and promotion of metastatic progression of 
cancer cells (Peluso et al., 2010). Protein C-ets-1 (ETS1) is a transcription factor that may 
control the differentiation, survival and proliferation of cells and may also regulate 
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angiogenesis (Kalet et al., 2012). N-myc proto-oncogene protein (NMYC) is transcription 
factor found in cancer cells and for efficient DNA binding requires dimerization with another 
protein (MAX) (Myzukami at al., 1995). Hypoxia-inducible factor 1 (HIF1) is expressed in most 
tissues and overexpressed in the majority of common cancers (Francesco et al., 2013). 
To investigate whether the sequence surrounding these candidates cis-regulatory SNPs 
can indeed bind TF, we analysed protein-DNA interactions through EMSA, using 
oligonucleotides containing the SNPs of interest. We performed several experiments, but did 
not detect any shift, corresponding to a positive protein-DNA interaction. However, we 
believe that our nuclear extracts might not have been optimal, as the positive control 
(primer FGFR2-13) used to evaluate the quality of the extracts did not show a shift as 
expected. We have two possible explanations: (1) there is indeed no interaction between TFs 
and our oligonucleotides, therefore these SNPs are not cis-regulatory; and (2) the TF can 
bind to our oligonucleotides but the extracts are suboptimal. We will carry out further 
experiments to resolve this issue. If the second scenario is confirmed, we will study whether 
this binding is confirmed by in vivo analysis through Chromatin Immunoprecipitation (ChIP). 
In the Genome Browser there is evidence of the existence of enhancers and active 
chromatin in our region of interest. We propose to extract the nuclear proteins of breast 
cancer cell lines using a different protocol (the NE-PER Nuclear and Cytoplasmic Extraction 
Reagents). If the protein-DNA interaction will be confirmed, the Chromatin 
Immunoprecipitation (ChIP) method will be used to study this interaction in vivo. In ChIP 
experiments, protein complexes that contact with DNA are crosslinked to their binding sites, 
by treatment with formaldehydde. The chromatin is then sheared in short fragments, and 
the specific DNA fraction that interacts with the protein of interest is isolated by 
immunoprecipitation and is then sequenced (Schmidt et al., 2009). 
The central goal of this work was to study the cis-regulatory variants of TP53 in breast 
cancer. In this work, we did not confirm whether any of the candidate SNPs in this region 
may be causing DAE observed in TP53 gene. Therefore, we need to continue this work in 
order to obtain conclusive results. To investigate a link between cis-regulatory SNPs and 
breast cancer, we will have to compare their effect in normal and tumour samples in future 
work. 
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